Suchergebnisse - "Zhong, Runbo"

PubPharm (95)

1

Prognostic value of pretreatment procalcitonin and neutrophil-lymphocyte ratio in extensive-stage small-cell lung cancer

enthalten in: Cancer biology & therapy | 2024

von Chen, D. | Xu, J. | Zhao, Y. | +2

2

Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer

enthalten in: The oncologist | 2024

von Xu, Y. | Ji, H. | Zhang, Y. | +5

3

Schwann cell-derived exosomes promote lung cancer progression via miRNA-21-5p

enthalten in: Glia | 2024

von Zhou, Y. | Zhang, Y. | Xu, J. | +9

4

Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study)

enthalten in: The clinical respiratory journal | 2023

von Zhang, B. | Zhong, H. | Shi, C. | +10

5

Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy

enthalten in: International journal of cancer | 2023

von Yu, L. | Hu, Y. | Xu, J. | +5

6

Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression

enthalten in: Translational oncology | 2023

von Xu, Y. | Xu, J. | Qiao, R. | +3

7

Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients : a retrospective comparative cohort study

enthalten in: Translational lung cancer research | 2023

von Yu, L. | Xu, J. | Qiao, R. | +3

8

Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis : results from the ALTER 0303 phase 3 randomized clinical trial

enthalten in: Journal of cancer research and clinical oncology | 2023

von Shen, Y. | Lu, J. | Hu, F. | +6

9

Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer

enthalten in: Cancer medicine | 2023

von Yu, L. | Xu, J. | Qiao, R. | +3

10

Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery

enthalten in: International journal of nanomedicine | 2023

von Lu, J. | Lou, Y. | Zhang, Y. | +7

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]